<DOC>
	<DOCNO>NCT01669343</DOCNO>
	<brief_summary>The purpose study examine key patient factor , include body size affect well letrozole suppresses circulate estrogen level . This study two component : ( 1 ) Part A - observational phase evaluate impact vitamin D obesity estrogen suppression post-menopausal woman already receive letrozole treatment , ( 2 ) Part B - interventional phase woman body mass index ( BM ) &gt; 25 kg/m2 . If BMI patient factor reduce effectiveness letrozole , modification treatment recommendation study test high dose letrozole may need maximize benefit treatment minimize risk breast cancer come back .</brief_summary>
	<brief_title>Aromatase Inhibitor Host Factors Study</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Postmenopausal female patient histological confirm diagnosis estrogen receptor and/or progesterone receptor positive breast cancer ( Stage IIII ) complete local therapy Currently prescribe take letrozole 2.5 mg daily minimum 3 month Willing provide write informed consent participate experimental arm : body mass index ( BMI ) &gt; 25 kg/m2 Known abnormal liver renal function define : 1 . Serum Creatinine &gt; 1.25 time institutional upper limit normal ( ULN ) Calculated Creatinine Clearance &lt; 40 mL/min 2 . Serum Bilirubin , AST ALT &gt; 1.5 time ULN Presence persistent local know metastatic cancer</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Aromatase Inhibitors</keyword>
</DOC>